This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Jane Seagal, PhD
Vice President, Antibody Discovery at AlivaMab Biologics


Jane has over a decade of experience in antibody drug discovery using in vivo approaches. Prior to joining AlivaMab Biologics, Jane led the In Vivo Antibody Discovery team at AbbVie, where she introduced and implemented multiple technology platforms, including hybridoma automation and direct antibody cloning from human patient samples. Jane has led projects across diverse therapeutic areas and enabled antibody discovery campaigns resulting in several clinical candidate molecules.

Agenda Sessions

  • Celebrating Diversity: AlivaMab® Discovery and Engineering Platforms for Novel Biologic Therapeutics